Skip to main content

Day: February 19, 2021

Balchem Corporation Reports Record Fourth Quarter Sales of $180.7 Million and Net Earnings of $22.2 Million, GAAP EPS of $0.68 and Adjusted EPS of $0.83

NEW HAMPTON, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC) reported today fourth quarter net earnings of $22.2 million for 2020, compared to net earnings of $20.4 million for the fourth quarter 2019. Fourth quarter adjusted net earnings(a) were $26.9 million, compared to $28.4 million in the prior year quarter. Fourth quarter adjusted EBITDA(a) was $43.6 million, compared to $40.0 million in the prior year quarter. Balchem Corporation also reported for the full year 2020 net earnings of $84.6 million, compared to net earnings of $79.7 million for 2019. Full year adjusted net earnings(a) were $107.8 million, compared to $103.7 million in the prior year, and full year adjusted EBITDA(a) was $174.2 million, compared to $160.0 million in the prior year.Fourth Quarter 2020 Financial Highlights:Record net sales...

Continue reading

AVANCE – Key information relating to the dividend for the fourth quarter, 2020

Key information relating to the dividend to be paid by Avance Gas Holding Ltd. for the fourth quarter 2020:Dividend amount: $0.11Declared currency: USDLast day including right: 3 March, 2021Ex-date: 4 March, 2021Record date: 5 March, 2021Payment date: On or about 19 March, 2021Date of approval: 18 February, 2021This information is published in accordance with the requirements of the Continuing Obligations.

Continue reading

Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors

PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of directors, effective Feb. 18. Dr. Gowen is chief executive officer of Tamuro Bio, a post that she has held since July 2019.“We are immensely excited to have Maxine join our board of directors,” said Dr. Bruce Goldsmith, president and chief executive officer of Passage Bio. “Her public company leadership and deep clinical development expertise will provide tremendous support to Passage Bio as we transition to a clinical development organization in the first half of 2021.”Tadataka Yamada, M.D., chairman of the Passage Bio board of directors and company...

Continue reading

Axsome Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in two upcoming investor conferences:10thAnnual SVB Leerink Global Healthcare Conference, on February 24, 2021 at 2:20 PM Eastern Time. Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat.Cowen 41stAnnual Health Care Conference, on March 1, 2021 at 11:00 AM Eastern Time. Dr. Tabuteau will participate in a virtual fireside chat.A live webcast and archive of the events can be viewed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com.About Axsome Therapeutics, Inc.Axsome Therapeutics, Inc. is a biopharmaceutical...

Continue reading

Cloud Storage Market to Exhibit 6.3% CAGR by 2027 Backed by Increasing Focus on Power Generation in APAC Region, says Fortune Business Insights™

Pune, India, Feb. 19, 2021 (GLOBE NEWSWIRE) — The global cloud storage market is set to gain traction from the rising adoption of autonomous systems and machine learning. Besides, the introduction to unique video systems, internet of things (IoT), and remote sensing technologies are driving the market growth. This information is provided by Fortune Business Insights™ in a recent study, titled, “Cloud Storage Market size, Share & Industry Analysis, By Component (Storage Model, and Services), By Deployment (Private, Public, and Hybrid), By Enterprise Size (SMEs, and Large Enterprises), By Vertical (BFSI, IT and Telecommunication, Government and Public Sector, Manufacturing, Healthcare and Life Sciences, Retail and Consumer Goods, Media and Entertainment, and Others), and Regional Forecast, 2021-2028.” The study further mentions...

Continue reading

Scatec reaches financial close for its first project in Pakistan

Oslo, 19 February 2021: Scatec and its local partner Nizam Energy have closed financing for the 150 MW Sukkur solar power project with a total investment of about USD 100 million.FMO, the Dutch development bank, Faysal Bank, Bank of Punjab and PAK Kuwait Investment have signed credit agreements for the non-recourse debt financing of the Sukkur project. Half of the debt quantum is provided by FMO under a credit facility of USD 39 million and the other half by the three local commercial lenders under PKR denominated credit facilities of an aggregated PKR 2.2 billion. The credit facilities cover up to 75% of the total project cost.“We are proud to complete financing of our first project in Pakistan together with our partners. The Government plans to increase the share of renewable energy to 30% by 2030 and we look forward to supporting this...

Continue reading

Admicom Oyj: Admicom Oyj:n varsinaisen yhtiökokouksen päätökset 19.2.2021

ADMICOM OYJ SISÄPIIRITIETO 19.2.2021 KLO 13:35Admicom Oyj:n varsinaisen yhtiökokouksen päätökset 19.2.2021Admicom Oyj:n varsinainen yhtiökokous 19.2.2021 vahvisti yhtiön tilinpäätöksen vuodelta 2020 ja myönsi vastuuvapauden hallituksen jäsenille sekä toimitusjohtajalle päättyneeltä tilikaudelta 2020.Päätökset ovat luettavissa kokonaisuudessaan yhtiökokouksen pöytäkirjasta Admicom Oyj:n verkkosivuilla osoitteessa www.admicom.fi/sijoittajille/yhtiokokous viimeistään 19.2.2021.Voitonjako ja osingonmaksuYhtiökokous vahvisti tilikaudelta 1.1.-31.12.2020 maksettavaksi osingoksi 0,91 eur/osake, eli yhteensä 4 484 205,18 euroa. Osingonmaksupäiväksi vahvistettiin 2.3.2021, varojenjaon täsmäytyspäivän ollessa 23.2.2021. Todettiin, että osinkoa ei makseta yhtiön hallussa oleville omille osakkeille.Emoyhtiön voitonjakokelpoiset varat ovat 17 127 781,97...

Continue reading

Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) — Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 4:20 p.m. ET.The live webcast will be available in the investor section of the company’s website at www.metacrine.com. The webcast will be archived for 60 days following the presentation.About MetacrineMetacrine, Inc. (Nasdaq: MTCR) is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. Metacrine has...

Continue reading

SEACOR Holdings Announces Results for the Fourth Quarter Ended December 31, 2020

FORT LAUDERDALE, Fla., Feb. 19, 2021 (GLOBE NEWSWIRE) — SEACOR Holdings Inc. (NYSE:CKH) (the “Company”) today announced its results for the fourth quarter ended December 31, 2020:Net income attributable to stockholders for the quarter ended December 31, 2020 was $10.8 million ($0.52 per diluted share) compared with a net loss of $(1.9) million ($(0.10) per diluted share) for the quarter ended December 31, 2019.Operating income for the quarter ended December 31, 2020 was $13.3 million compared with $2.6 million for the quarter ended December 31, 2019.“Cash Earnings” for the quarter ended December 31, 2020 were $23.0 million compared with $18.5 million for the quarter ended December 31, 2019.The Company uses the non-GAAP financial measures “Cash Earnings” and OIBDA in this release; a reconciliation to their closest U.S....

Continue reading

Auction result of Treasury Bonds – RIKB 28 1115 – RIKS 30 0701

Series  RIKB 28 1115 RIKS 30 0701Settlement Date  02/24/2021 02/24/2021Total Amount Allocated (MM)  780 2,360All Bids Awarded At (Price / Yield)  111.482 / 3.290 123.607 / 0.640Total Number of Bids Received  8 16Total Amount of All Bids Received (MM)  1,760 3,160Total Number of Successful Bids  4 13Number of Bids Allocated in Full  4 11Lowest Price / Highest Yield Allocated  111.482 / 3.290 123.607 / 0.640Highest Price / Lowest Yield Allocated  111.770 / 3.250 124.018 / 0.600Lowest Price / Highest Yield Allocated in Full  111.482 / 3.290 123.608 / 0.640Weighted Average of Successful Bids (Price/Yield)  111.529 / 3.280 123.727 / 0.628Best Bid (Price / Yield)  111.770 / 3.250 124.018 / 0.600Worst Bid (Price / Yield)  111.220 / 3.330 123.403 / 0.660Weighted Average of All Bids Received (Price /...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.